Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04787965 · ClinicalTrials.gov registry record
Opicapone Treatment Initiation Open-Label Study
A clinical trial of Parkinson Disease, sponsored by Neurocrine Biosciences.
- Completed
- Registry status
- 239
- Enrollment target
- 6
- Study locations
NCT04787965 is a study of Parkinson Disease that has completed, run by Neurocrine Biosciences. The registered enrollment target is 239 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (96% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT04787965, a study of Parkinson Disease, has completed, sponsored by Neurocrine Biosciences.
- COMPLETED
- Registry status
- 239 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is an observational study to describe the treatment patterns and clinical outcomes observed with use of ONGENTYS as adjunctive treatment to levodopa/carbidopa in Parkinson's disease patients experiencing "off" episodes with motor fluctuations
Conditions Studied
Interventions
- DRUG Opicapone
Study Locations (6)
Virginia
- Neurocrine clinical site - Christiansburg
- Neurocrine clinical site - Norfolk
California
- Neurocrine clinical site - Los Gatos
Tennessee
- Neurocrine clinical site - Memphis
Washington
- Neurocrine clinical site - Auburn
West Virginia
- Neurocrine clinical site - Crab Orchard
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2022-08-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04787965
The ClinicalTrials.gov registry entry for NCT04787965 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 239 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (96% lower). The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Opicapone is the first listed.
NCT04787965 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Virginia, California, Tennessee.
Frequently Asked Questions
What is clinical trial NCT04787965 about?
NCT04787965 is a clinical study titled "Opicapone Treatment Initiation Open-Label Study". This is an observational study to describe the treatment patterns and clinical outcomes observed with use of ONGENTYS as adjunctive treatment to levodopa/carbidopa in Parkinson's disease patients experiencing "off" episodes with motor fluctuations
What is the current status of trial NCT04787965?
This trial is currently completed. The enrollment target is 239 participants. The study started on 2021-03-01. Estimated completion is 2022-08-04.
What conditions does trial NCT04787965 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT04787965?
The interventions under investigation include: Opicapone (DRUG).
Who is sponsoring clinical trial NCT04787965?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04787965 being conducted?
This trial has 6 study locations across California, Tennessee, Virginia, Washington, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
RECRUITING
-
University of Delaware Parkinson's Disease Registry
RECRUITING
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.